- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Chevron seems to be a slightly more attractive investment, but that's not to say Exxon isn't worth another look.
Its business results don't appear to be a problem, but Nike's valuation moving forward might be.
Israel-based Teva doesn't have to do anything spectacular to warrant a second look.
Chuck Carnevale differs from Jim Cramer in his comparison of the two giants of the pharmacy services industry.
These 12 charts reveal why Amazon is really amazing and befuddling at the same time.
Starbucks is a great company at a lousy price.
Nothing runs like the machinery maker when times are good.
Here's what's behind the rise in Cisco stock.
Norfolk Southern is an above-average dividend growth stock that is currently attractively valued.
Health care is one sector where you can still find a bargain, like Stryker.